Since 2016, several vaccines for the Zika virus have been under development. However, there are currently no FDA-approved vaccines for the virus. The goal of a Zika virus vaccine typically is to produce specific antibodies against the Zika virus to prevent infection and severe disease. The challenges in developing a safe and effective vaccine include limiting side effects such as Guillain-Barré syndrome, a potential consequence of Zika virus infection. Most vaccine development for the Zika virus typically uses mRNA technology since it tends to produce a more rapid vaccine response than other technologies.
